ClinicalTrials.gg

Program

lanifibranor

Also written as “IVA337” and “Lanifibranor”.

In Sino Biopharmaceutical's pipeline, 泛PPAR激动剂. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Scleroderma, Diffuse, led by 2 companies.

Furthest: phase 3, since Apr 16, 20216 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inventiva Pharma51 open or runningphase 3since Apr 16, 2021Jun 30, 2015none ahead
Sino Biopharmaceutical10 open or runningphase 1since Nov 7, 2023Nov 7, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as Lanifibranor, phase 3, as of Nov 16, 2026 (source).

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2015First study: phase 2 study in Scleroderma, DiffuseNew to Inventiva PharmaInventiva Pharma · NCT02503644 · 145 enrolled · Bulgaria, France, Germany and more
  2. Dec 22, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseInventiva Pharma · NCT03008070 · 247 enrolled · United States, Australia, Austria and more
  3. Mar 1, 2019Phase 1 study in Healthy SubjectsInventiva Pharma · NCT03866369 · 36 enrolled · Germany
  4. Apr 16, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseInventiva Pharma · NCT04849728 · 1,000 enrolled · United States, Argentina, Australia and more
  5. Jan 26, 2022Phase 2 study in Non-alcoholic Fatty Liver DiseaseInventiva Pharma · NCT05232071 · 39 enrolled · United States, Belgium, France and more
  6. Nov 7, 2023Sino Biopharmaceutical's first study: phase 1 study in PharmacokineticNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06126562 · 24 enrolled · China

TargetBeta

“泛PPAR激动剂”the company's pipeline, read by Claude · source

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
chiglitazarruleChipscreen Biosciencesphase 39

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06126562Pharmacokinetic · China1CompletedSino BiopharmaceuticalNov 28, 202324
NCT05232071Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more2CompletedInventiva PharmaMay 8, 202439
NCT04849728Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3Active, not recruitingInventiva PharmaSep 29, 20261,000
NCT03866369Healthy Subjects · Germany1CompletedInventiva PharmaAug 27, 201936
NCT03008070Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more2CompletedInventiva PharmaFeb 20, 2020247
NCT02503644Scleroderma, Diffuse · Bulgaria, France, Germany and more2CompletedInventiva PharmaOct 2018145

How it is read

Names in the registry

  • “IVA337”, 4 entries
  • “Lanifibranor”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.